The proposed Salk Microarray core overcomes limitations of the Illumina microarray system, in that currently there are only arrays available for human and mouse gene expression analysis. Thus, to enable global gene expression analysis for other model organisms used in the neurosciences, as well as a variety of microarray approaches beyond gene expression assays^ a satellite core facility at the Salk will provide Affymetrix-based array analysis. The Salk facility is currently a core in their Cancer Center, and increasing its capacity will provide previously unavailable access to La Jolla area neuroscientists. The Salk Microarray facility, begun in 1999, has also evolved, first making in-house spotted arrays and then later adding the Affymetrix platform for manufactured arrays. While Affymetrix arrays have become the predominant approach for analysis of gene expression in the Salk core, an active effort and capacity for custom printing of spotted arrays and their analysis has been maintained in this facility. The Salk facility also provides service and training for real-time PCR analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Center Core Grants (P30)
Project #
5P30NS057096-04
Application #
7925705
Study Section
Special Emphasis Panel (ZNS1)
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
4
Fiscal Year
2009
Total Cost
$146,352
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Singec, Ilyas; Crain, Andrew M; Hou, Junjie et al. (2016) Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic Profiling. Stem Cell Reports 7:527-542
Kim, Changyoun; Lv, Guohua; Lee, Jun Sung et al. (2016) Exposure to bacterial endotoxin generates a distinct strain of ?-synuclein fibril. Sci Rep 6:30891
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97
Kim, Changyoun; Lee, He-Jin; Masliah, Eliezer et al. (2016) Non-cell-autonomous Neurotoxicity of ?-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol 25:113-9
Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10
Tang, Bin; Wang, Tingting; Wan, Huida et al. (2015) Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome. Proc Natl Acad Sci U S A 112:E4697-706
Rockenstein, Edward; Overk, Cassia R; Ubhi, Kiren et al. (2015) A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies. PLoS One 10:e0121570
Hoefer, Melanie M; Sanchez, Ana B; Maung, Ricky et al. (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221-34
Valera, Elvira; Mante, Michael; Anderson, Scott et al. (2015) Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation 12:93

Showing the most recent 10 out of 105 publications